SG&A Expense (Quarterly) Chart

View SG&A Expense (Quarterly) for IDRSF.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View SG&A Expense (Quarterly) Chart
Start Trial

Historical SG&A Expense (Quarterly) Data

View and export this data back to 2017. Start Trial.
Date Value
December 31, 2025 77.58M
September 30, 2025 64.98M
June 30, 2025 61.75M
March 31, 2025 58.29M
December 31, 2024 78.64M
September 30, 2024 60.00M
June 30, 2024 77.39M
March 31, 2024 77.54M
December 31, 2023 89.04M
September 30, 2023 72.44M
June 30, 2023 131.27M
March 31, 2023 126.46M
December 31, 2022 137.96M
September 30, 2022 137.57M
June 30, 2022 130.54M
March 31, 2022 107.16M
December 31, 2021 111.73M
September 30, 2021 54.45M
Date Value
June 30, 2021 42.84M
March 31, 2021 32.01M
December 31, 2020 38.72M
September 30, 2020 23.92M
June 30, 2020 18.68M
March 31, 2020 17.56M
December 31, 2019 19.41M
September 30, 2019 15.38M
June 30, 2019 16.57M
March 31, 2019 15.50M
December 31, 2018 16.24M
September 30, 2018 15.63M
June 30, 2018 15.58M
March 31, 2018 14.48M
December 31, 2017 15.95M
September 30, 2017 13.37M
June 30, 2017 0.00
March 31, 2017 20.57M

SG&A Expense (Quarterly) Range, Past 5 Years

View SG&A Expense (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

SG&A Expense (Quarterly) Benchmarks

View SG&A Expense (Quarterly) Benchmarks
Start Trial
BeOne Medicines Ltd. 556.75M
AC Immune SA 5.326M
CRISPR Therapeutics AG 17.18M
ADC Therapeutics SA 22.60M
MoonLake Immunotherapeutics 15.51M